Pain perception and chronic pain in humans: in search of genetic factors and biomarkers

Pain perception and chronic pain in humans: in search of genetic factors and biomarkers - Pain genetics and biomarkers

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38099

Enrollment

20000

Registered

2014-01-30

Start date

2015-05-12

Completion date

Unknown

Last updated

2024-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aandoeningen die door middel van een operatie worden behandeld patients undergoing an operation

Interventions

None listed

Eligibility

Age

16 Years to 99 Years

Inclusion criteria

Inclusion criteria: Ages 18-80yr; consenting; caucasian; planned surgery; categories of surgery: extremities, extra-abdominal, intra-abdominal, intra-thoracic, extra-thoracic; able to understand and perform QST paradigms; able to understand and answer questionnaires; if selected for EEG/MRI, additionally: able to undergo these procedures; no psychiatric or neurological diseases

Exclusion criteria

Exclusion criteria: Non-consent, inability to give consent, neurological and psychiatric disease interfering with QST and questionnaires, unplanned and emergency surgery

Design outcomes

Primary

Measure	Time frame
1) understanding of the link between genes and pain sensitivity, pain modulation and vulnerability to develop chronic pain; 2) prevalence and intensity of chronic pain 6, 12 and 24 months after surgery.	—

Secondary

Measure	Time frame
1) genotype: genome-wide association analysis and candidate gene analysis, as well as (on the longer term) exome and whole genome sequencing; 2) expression profiles: RNA and protein levels; 3) phenotype: measures of pain sensitivity (thresholds) and modulation (windup and Diffuse Noxious Inhibitory Control (DNIC) paradigms) for different modalities (electric, pressure, temperature) and tissues (skin, muscle). 4) measure of Event Related Potentials (ERP) following painful stimuli; 5) (functional) Magnetic Resonance Imaging (MRI) data of brain structures, pain processing and modulation. These factors will be related to each other, to pain sensitivity and to the development of chronic pain.	—

Measure

Time frame

1) genotype: genome-wide association analysis and candidate gene analysis, as well as (on the longer term) exome and whole genome sequencing; 2) expression profiles: RNA and protein levels; 3) phenotype: measures of pain sensitivity (thresholds) and modulation (windup and Diffuse Noxious Inhibitory Control (DNIC) paradigms) for different modalities (electric, pressure, temperature) and tissues (skin, muscle). 4) measure of Event Related Potentials (ERP) following painful stimuli; 5) (functional) Magnetic Resonance Imaging (MRI) data of brain structures, pain processing and modulation. These factors will be related to each other, to pain sensitivity and to the development of chronic pain.

—

Countries

Netherlands

Outcome results